Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.
about
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patientsDose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practicePharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsMight ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data?Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.A sensitive and specific liquid chromatography/tandem mass spectrometry method for quantification of nevirapine and its five metabolites and their pharmacokinetics in baboonsGenome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography techniqueEffect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of Non-nucleoside Reverse Transcriptase Inhibitors.CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.Hypersensitivity reactions to HIV therapy.Pharmacogenomics of antimicrobial agents.Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of lifeExploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in MalawiansDistribution of human CYP2C8*2 allele in three different African populationsToxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descentNevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsIndividualization of antiretroviral therapy.Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceSuboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDSAssociation of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.Advances in pharmacogenomics of antiretrovirals: an update.Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmissionNew era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature.Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.The impact of pharmacogenetics on HIV therapy.Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.Pharmacogenomics of CYP3A: considerations for HIV treatment.Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
P2860
Q24602072-6F0BE106-2409-49E0-928C-31A4B1BCDD7DQ24609011-E3B80881-6036-4A27-989B-D829F1B5094CQ27692040-524C205B-D1D2-4947-AD46-E15A1E950DD9Q28069383-592765C0-2636-4642-85D9-B119855D29DDQ28555028-2CD54601-1C0A-43B7-9942-5FBB25FBFF4CQ33375532-4F6EF793-E5AE-4832-9AD7-C32174DF33E4Q33394593-BEC30C0B-B27E-444F-BE8D-7D6427B8BE9AQ33514519-D955D868-F2F7-40FB-99E2-3637E911F06EQ33589777-EA41FC5B-8AE9-4D3F-BC6D-0E43C7209D8DQ33720712-608A574E-D450-47A3-BBF2-9239775A0B08Q33850152-05F6D9CB-3F50-49B8-8FCA-C93009F1DF1FQ34150925-0FDBF11A-B2DF-4918-8F86-A908735CC795Q34443184-A76C8360-E1CC-421D-9617-AA33C621344BQ34495636-14E8DF76-D407-4A3F-B218-A0AE4827858DQ34975110-FDFD3D04-B1C9-4A9E-A8FF-96BC0B4CD3CCQ34976463-99F8CEAD-242C-4528-895A-0DA44E0232CDQ34977413-8B3AD1D1-DC37-456E-84E9-F7E6FABB2080Q35238134-EFC37750-68D7-46AD-8EDB-9D64EA02AFBFQ35796733-875A20E7-9FA6-44ED-8449-577A34B084A8Q35963368-AA5E2DA1-13FD-4983-A958-CD9B3D02F5C4Q36070182-10943879-ADC2-4E87-A5A3-16F4746FBC1BQ36276839-C6E44C1E-C8D5-498C-9B53-D0101D04A976Q36437792-8DDEDB1B-9721-43DA-BCD7-8AEB1E951D5FQ36441423-6C6F1372-B105-4736-BF65-CD565FAC1AB9Q36650954-E9AF3624-91CD-4605-8D62-E47D71DACF90Q36657589-4714DEAA-B0A3-4D76-86D3-D71768CF3D1BQ36676527-01992E62-9A27-4A95-B67A-FFE059F46569Q36682500-C09FCC29-1EAD-4FDE-960C-D22C7B9B0806Q36708715-EEDFA7AF-5668-49CE-9262-AB154A3B004BQ36740238-99F9104E-E230-4791-80E0-B5168544C0A6Q36885659-6D022C89-6CA6-4C25-90FE-444D32FDC55DQ36966025-6317B0A3-C59A-484B-BF88-06DDAF7A5492Q37037070-FDFF6AF4-DA2A-44E0-BD6A-D88313DCB664Q37124261-6538364A-9831-496A-81FB-D05D1AADACDCQ37173207-4691C576-07C7-4E85-9BFA-321E0D7A14F8Q37278622-D275EE4B-0F94-4900-8117-BACFBCBD6980Q37405140-E6AD2B0C-454F-42C7-88E4-B926055B3399Q37417511-7921690C-63E0-40A6-B6DB-0730162793F5Q37419542-070A5133-A88B-4661-8106-8B55070B2BAAQ37444323-1500FB69-07C5-4A03-8701-D7B68182F56A
P2860
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Cytochrome P450 2B6 (CYP2B6) G ...... V-infected patients in Uganda.
@en
type
label
Cytochrome P450 2B6 (CYP2B6) G ...... V-infected patients in Uganda.
@en
prefLabel
Cytochrome P450 2B6 (CYP2B6) G ...... V-infected patients in Uganda.
@en
P2093
P2860
P1433
P1476
Cytochrome P450 2B6 (CYP2B6) G ...... V-infected patients in Uganda.
@en
P2093
E Formentini
F Mbamanya
P Mugyenyi
R M Alfaro
S R Penzak
V Natarajan
P2860
P356
10.1111/J.1468-1293.2007.00432.X
P577
2007-03-01T00:00:00Z